EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will examine whether the new investigational drug EPO906, given by intravenous
infusion (IV directly into the vein), is effective in shrinking tumors and preventing the
growth of cells that cause ovarian, fallopian, or peritoneal cancers. Recruitment in the
United States is complete but the study is still enrolling in other countries.